EWA
CRDF icon

EverSource Wealth Advisors’s Cardiff Oncology CRDF Stock Holding History

EverSource Wealth Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45K Buy
1,115
+760
+214% +$1.21K ﹤0.01% 3847
2026
Q1 		$576 Buy
+355
New +$729 ﹤0.01% 4030
2025
Q2 		– Sell
-2
Closed -$6 – 4273
2025
Q1 		$6 Buy
+2
New +$8 ﹤0.01% 4002

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EverSource Wealth Advisors's CRDF Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Cardiff Oncology (CRDF) stake by 214% in Q2 2026, buying an estimated $1.21K and bringing the position to 1,115 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

EverSource Wealth Advisors first reported a position in CRDF in Q1 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • EverSource Wealth Advisors held 1,115 shares of Cardiff Oncology worth $1.45K as of Q2 2026.
  • EverSource Wealth Advisors bought 760 Cardiff Oncology shares in Q2 2026, an estimated $1.21K.
  • Cardiff Oncology made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3847 holding.
  • EverSource Wealth Advisors first reported a position in Cardiff Oncology in Q1 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.